Reference Center of Hereditary Cancer

Oncogenetic counseling, genetic testing and reimbursement shall be carried out in accordance with the order of 31.12.2014 approved by the Minister of Health of the Republic of Lithuania V-1458 ("Description of the indications for the provision of genetic health care services and reimbursement of the costs of these services PSDF budget").

Genetic testing is reimbursed when a patient has the following symptoms

• breast carcinoma diagnosed in a person less than 50 years of age,
• breast carcinoma with negative results in all three studies of estrogen, progesterone and HER2 receptors (ER, PER, HER2 (-),
• medullary breast carcinoma,
• reciprocal (primary) breast carcinoma,
• male breast carcinoma,
• breast and ovarian / fallopian tube / peritoneal / pancreatic / gastric carcinoma / melanoma in the same patient,
• breast carcinoma detected in at least two first-degree relatives,
• invasive carcinoma of the ovaries / fallopian tubes / peritoneum,
• 10 and more colon polyps,
• colon carcinoma diagnosed in a person less than 50 years of age,
• uterine (endometrial) carcinoma diagnosed in a woman under 50 years of age,
• Molecular, histological and / or immunohistochemical evidence of possible hereditary cancer syndromes (microsatellite instability, MMR protein deficiency, etc.) in tumor tissue;
• two (or more) Lynch spectrum malignancies (synchronous / metachronous)
• medullary thyroid carcinoma,
• pheochromocytoma,
• adrenocortical carcinoma,
• gastrinoma,
• small intestine carcinoma,
• neuroendocrine tumors of the pancreas (NET) and hyperparathyroidism,
• cerebral and / or retinal haemangioblastoma / angiomatosis,
• vestibular schwanoma (neurolemoma) and / or multiple meningiomas,
• sarcoma (except Ewing type),
• reciprocal renal angiomiolipoma,
• oncological disease diagnosed in persons less than 50 years of age (excluding oncohematologic diseases, lung and cervical malignancies),
• reciprocal malignant tumors of the porous organs,
• clinically suspected autosomal dominantly inherited cancer syndromes (e.g. tuberous sclerosis complex, neurofibromatosis (type I and II), Peutz-Jeghers, Cowden, Li-Fraumeni, breast or ovarian cancer, Lynch, von Hippel-Lindau syndrome , multiple endocrine neoplasia, hereditary pheochromocytoma-paraganglioma, familial adenomatous polyposis, juvenile polyposis, etc.),
• clinically suspected autosomal recessive inherited cancer syndromes (e.g., MUTYH-associated polyposis, Nijmegen syndrome, ataxia-telangiectasia, etc.).

Healthy individuals are reimbursed for genetic testing if their relatives have a genetically confirmed hereditary cancer syndrome (i.e., a detected gene mutation). In other cases, patients can sign up for paid services and discharge (more at genetika.lt)